Related references
Note: Only part of the references are listed.How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient
Elsa Hansen et al.
PLOS BIOLOGY (2017)
Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
Urszula Ledzewicz et al.
CANCER LETTERS (2017)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
Boyang Zhao et al.
CELL (2016)
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
Nicholas McGranahan et al.
CANCER CELL (2015)
Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort
Franziska Michor et al.
CELL (2015)
Targeting cancer with kinase inhibitors
Stefan Gross et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Barbie Taylor-Harding et al.
ONCOTARGET (2015)
The Model Muddle: In Search of Tumor Growth Laws
Philip Gerlee
CANCER RESEARCH (2013)
The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit
Sabrina L. Spencer et al.
CELL (2013)
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic et al.
ELIFE (2013)
Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
Ariosto S. Silva et al.
CANCER RESEARCH (2012)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
An Integrated Chemical Biology Approach Provides Insight into Cdk2 Functional Redundancy and Inhibitor Sensitivity
Aude Echalier et al.
CHEMISTRY & BIOLOGY (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways
Dai Horiuchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration
M. Kasim Diril et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
On measuring selection in experimental evolution
Luis-Miguel Chevin
BIOLOGY LETTERS (2011)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301
Huw D. Thomas et al.
EUROPEAN JOURNAL OF CANCER (2011)
The CDK inhibitors in cancer research and therapy
Jonas Cicenas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Switching Cdk2 On or Off with Small Molecules to Reveal Requirements in Human Cell Proliferation
Karl A. Merrick et al.
MOLECULAR CELL (2011)
A theoretical quantitative model for evolution of cancer chemotherapy resistance
Ariosto S. Silva et al.
BIOLOGY DIRECT (2010)
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Stefano Campaner et al.
NATURE CELL BIOLOGY (2010)
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
W. Ruprecht Wiedemeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A change of strategy in the war on cancer
Robert A. Gatenby
NATURE (2009)
Spheroid-based drug screen: considerations and practical approach
Juergen Friedrich et al.
NATURE PROTOCOLS (2009)
Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle
Liliana Krasinska et al.
CELL CYCLE (2008)
Molecular basis of drug resistance in Aurora kinases
Fiona Girdler et al.
CHEMISTRY & BIOLOGY (2008)
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
Lisheng Wang et al.
BLOOD (2007)
Cdk1 is sufficient to drive the mammalian cell cycle
David Santamaria et al.
NATURE (2007)
Cdk2 knockout mice are viable
C Berthet et al.
CURRENT BIOLOGY (2003)
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
S Ortega et al.
NATURE GENETICS (2003)
Proliferation of cancer cells despite CDK2 inhibition
O Tetsu et al.
CANCER CELL (2003)
A cellular automaton model of early tumor growth and invasion: The effects of native tissue vascularity and increased anaerobic tumor metabolism
AA Patel et al.
JOURNAL OF THEORETICAL BIOLOGY (2001)
Share Paper
